Pattern Bioscience, a privately held in vitro diagnostics company founded in 2016, is developing a clinical microbiology platform based on its patented phenotypic single-cell technology. Their Digital CultureTM technology provides more comprehensive and reliable diagnoses compared to rapid genotypic tests, allowing for faster and more accurate treatment decisions.